Abstract
A two-pronged approach to fighting cancer, oncolytic virotherapy (OV) combines direct tumor cytotoxicity with potentiation of anti-tumor immunity. Combining OVs and cell therapies, such as CAR-T and NK cells, has been proposed as an enhanced therapeutic approach. Additionally, it has been demonstrated that adding oncolytic virotherapy to combination medicines increases their therapeutic potential. This article explains the mechanisms underlying oncolytic viruses, the beneficial interactions between them and immune cell therapies, as well as the drawbacks and difficulties of this strategy. We highlight the novel approach of combining CAR T/NK cell treatments and oncolytic virotherapy, highlighting current developments and speculating on the future trajectories of this frontier in cancer immunotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Transactions on Materials, Biotechnology and Life Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
